Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A single center, prospective study to assess the efficacy of high flow nasal cannula (HFNC) in improving obstructive sleep apnea (OSA) parameters in patients with reduced tolerance to continuous positive airway pressure (CPAP) treatment.
A single center, prospective study. The study would include 30 patients diagnosed within the past 2 years with moderate to severe OSA (AHI>=15) at the Rabin Medical Center (RMC) sleep lab, and who are intolerant to CPAP treatment. Following signing an informed consent form, these patients would undergo polysomnography (PSG) while treated with HFNC. The HFNC PSG outcome measures will be compared to the baseline PSG done within the past 2 years and to an additional PSG while connected to a CPAP device.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High flow nasal cannula treatment | Experimental | Airvo 2 device will be used to administer high flow air during the night |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High flow nasal cannula | Device | We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Apnea Hypopnea Index (AHI) | Comparison of HFNC AHI to baseline AHI and to CPAP AHI | During at least 2 hours of sleep time |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of hypoxemia time | O2 saturation (SO2)<90% as measured by pulse oximeter | During at least 2 hours of sleep time |
| Minimal SO2% | During at least 2 hours of sleep time |
| Measure | Description | Time Frame |
|---|---|---|
| Percent rapid eye movement (REM) sleep | During at least 2 hours of sleep time | |
| Percent Deep sleep | During at least 2 hours of sleep time | |
| User experience with HFNC |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Avraham Unterman, MD | Contact | 972-39377221 | ramiun@clalit.org.il |
| Name | Affiliation | Role |
|---|---|---|
| Mordechai R Kramer, MD | Pulmonary Institute, Rabin Medical Center, Israel | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Adverse events reported while using HFNC | During at least 2 hours of sleep time |
| Sleep efficiency | During at least 2 hours of sleep time |
| Total sleep time | During at least 2 hours of sleep time |
To be assessed in the following morning with questionnaires |
| During at least 2 hours of sleep time |
| D020919 |
| Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |